A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas

Modern Pathology

Volumn 17, Issue 6, 2004, Pages 611-616

  Lin, Zhen Hua ^a   Han, Eun Mee ^a   Lee, Eung Seok ^a   Kim, Chul Whan ^a   Kim, Han Kyeom ^a   Kim, Insun ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

c kit; KIT; Papillary renal cell carcinoma

Indexed keywords

STEM CELL FACTOR;

ARTICLE; COILED BODY; EXON; GENE EXPRESSION; GENE MUTATION; GERM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INTRON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MAST CELL; MELANOCYTE; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL;

BASE SEQUENCE; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 2642565305     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800108     Document Type: Article

References (20)

1. Fleming S, O'Donnell M. Surgical pathology of renal epithelial neoplasms: recent advances and current status. Histopathology 2000;36:195-202.
2. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-989.
3. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-624.
4. Young AN, de Oliveira Salles PG, Lim SD, et al. Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol 2003;27:199-205.
5. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003;22:847-852.
6. Takahashi M, Sugimura J, Yang X, et al. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res 2003;89:157-181.
7. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-495.
8. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-2419.
9. Nio Y, Omori H, Toga T, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. Anticancer Drugs 2003;14:313-319.
10. Makhlouf HR, Remotti HE, Ishak KG. Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol 2002;26:493-497.
11. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-663.
14. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-993.
15. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-544.
16. Hornick JL, Fletcher CD. Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 2003;119:325-327.
17. Lucas DR, al-Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003;119:339-345.
18. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-1095.
19. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;9:4297-4300.
20. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.